These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 12666132)

  • 1. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
    Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
    Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
    Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
    Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
    Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
    Kuku I; Bayraktar MR; Kaya E; Erkurt MA; Bayraktar N; Cikim K; Aydogdu I
    Mediators Inflamm; 2005 Aug; 2005(3):171-4. PubMed ID: 16106104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity.
    Alexandrakis MG; Passam FH; Kyriakou DS; Christophoridou AV; Perisinakis K; Hatzivasili A; Foudoulakis A; Castanas E
    Am J Hematol; 2004 Feb; 75(2):101-6. PubMed ID: 14755377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of serum vascular endothelial growth factor and interleukin-6 in multiple myeloma].
    Shen JK; Dong LH; Qi H; Zhang GS
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Feb; 30(1):68-71. PubMed ID: 15871192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
    Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
    Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monitoring markers of bone turnover in multiple myeloma].
    Spicka I; Spacek P; Hulejová H; Procházka B; Cieslar P; Chrz M; Válková V; Klener P
    Vnitr Lek; 1999 Aug; 45(8):463-7. PubMed ID: 11045145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
    Urbańska-Ryś H; Robak T
    Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma.
    Hsia CY; Huo TI; Chiang SY; Lu MF; Sun CL; Wu JC; Lee PC; Chi CW; Lui WY; Lee SD
    Eur J Surg Oncol; 2007 Mar; 33(2):208-12. PubMed ID: 17140760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions.
    Coskun U; Bukan N; Sancak B; Günel N; Ozenirler S; Unal A; Yucel A
    Neoplasma; 2004; 51(3):209-13. PubMed ID: 15254675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease.
    Kitano M; Ogata A; Sekiguchi M; Hamano T; Sano H
    J Bone Miner Metab; 2005; 23(1):48-52. PubMed ID: 15616894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of hepatocyte growth factor in patients with breast cancer.
    Sheen-Chen SM; Liu YW; Eng HL; Chou FF
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procollagen I amino-terminal propeptide as a potential marker for multiple myeloma.
    Kowalska M; Druzd-Sitek A; Fuksiewicz M; Kotowicz B; Chechlinska M; Syczewska M; Walewski J; Kaminska J
    Clin Biochem; 2010 Apr; 43(6):604-8. PubMed ID: 20045402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients.
    Alexandrakis MG; Passam FH; Malliaraki N; Katachanakis C; Kyriakou DS; Margioris AN
    Clin Chim Acta; 2002 Nov; 325(1-2):51-7. PubMed ID: 12367766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.